Emerging advanced therapies such as CAR-T and gene therapies have the potential to cure previously intractable conditions with a single infusion. Unfortunately, these incredible treatments remain out of the reach of many due to current vector technology limiting efficacy, quality, and manufacturing viability.
Lentitek has a unique manufacturing technology that can significantly improve the production quality of the lentivirus vector used in advanced therapies and enable new applications such as in-vivo CAR-T and armoured CARs. Additionally, the improvement in manufacturing quality can lead to higher yields and improved product potency.
